Agomab Therapeutics NV has successfully closed a $100 million Series C financing round led by Fidelity Management & Research Company to advance its clinical pipeline focused on fibrotic diseases.
Target Company Information
Agomab Therapeutics NV, headquartered in Ghent, Belgium, is dedicated to pioneering innovative therapies aimed at resolving fibrosis and restoring organ function. Their research is deeply rooted in growth factor biology, enabling the development of novel treatment methods for fibrotic diseases. Agomab currently has a range of programs in its clinical pipeline, illustrating its commitment to transforming the landscape of treatment for conditions characterized by excessive fibrosis.
The company’s lead candidate, AGMB-129, recently entered a Phase 2a clinical trial focused on Fibrostenosing Crohn's Disease (FSCD), a serious condition affecting multiple patients suffering from this gastrointestinal disorder. With the recent FDA Fast Track designation granted to AGMB-129, Agomab is poised to make significant advancements in this critical area of healthcare.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biopharmaceutical sector in Belgium is robust, characterized by a rich ecosystem of innovation and collaboration among industry players. The country is home to numerous biotech firms, research institutions, and a supportive regulatory f
Similar Deals
Cochlear, Resmed, Nyxoah’s Chairman and Management → Nyxoah SA
2025
Fidelity Management & Research Company
invested in
Agomab Therapeutics NV
in 2023
in a Other deal
Disclosed details
Transaction Size: $100M